These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 18216871)

  • 1. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival.
    Tefferi A; Lasho TL; Huang J; Finke C; Mesa RA; Li CY; Wu W; Hanson CA; Pardanani A
    Leukemia; 2008 Apr; 22(4):756-61. PubMed ID: 18216871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
    Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications.
    Passamonti F; Rumi E; Pietra D; Elena C; Boveri E; Arcaini L; Roncoroni E; Astori C; Merli M; Boggi S; Pascutto C; Lazzarino M; Cazzola M
    Leukemia; 2010 Sep; 24(9):1574-9. PubMed ID: 20631743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea.
    Sirhan S; Lasho TL; Hanson CA; Mesa RA; Pardanani A; Tefferi A
    Am J Hematol; 2008 May; 83(5):363-5. PubMed ID: 18266209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia.
    Kittur J; Knudson RA; Lasho TL; Finke CM; Gangat N; Wolanskyj AP; Li CY; Wu W; Ketterling RP; Pardanani A; Tefferi A
    Cancer; 2007 Jun; 109(11):2279-84. PubMed ID: 17440984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele.
    Guglielmelli P; Barosi G; Specchia G; Rambaldi A; Lo Coco F; Antonioli E; Pieri L; Pancrazzi A; Ponziani V; Delaini F; Longo G; Ammatuna E; Liso V; Bosi A; Barbui T; Vannucchi AM
    Blood; 2009 Aug; 114(8):1477-83. PubMed ID: 19549988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival.
    Tefferi A; Lasho TL; Patnaik MM; Finke CM; Hussein K; Hogan WJ; Elliott MA; Litzow MR; Hanson CA; Pardanani A
    Leukemia; 2010 Jan; 24(1):105-9. PubMed ID: 19847199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical and prognostic relevance of driver mutations in 203 Taiwanese patients with primary myelofibrosis.
    Kuo MC; Lin TH; Sun CF; Lin TL; Wu JH; Wang PN; Huang YJ; Chang H; Huang TY; Shih LY
    J Clin Pathol; 2018 Jun; 71(6):514-521. PubMed ID: 29203554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis.
    Helbig G; Wieczorkiewicz A; Woźniczka K; Wiśniewska-Piąty K; Rusek A; Kyrcz-Krzemień S
    Med Oncol; 2012 Dec; 29(4):2379-84. PubMed ID: 22383244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients.
    Pardanani A; Guglielmelli P; Lasho TL; Pancrazzi A; Finke CM; Vannucchi AM; Tefferi A
    Leukemia; 2011 Dec; 25(12):1834-9. PubMed ID: 21691276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis.
    Rozovski U; Verstovsek S; Manshouri T; Dembitz V; Bozinovic K; Newberry K; Zhang Y; Bove JE; Pierce S; Kantarjian H; Estrov Z
    Haematologica; 2017 Jan; 102(1):79-84. PubMed ID: 27686378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of JAK2
    Latagliata R; Polverelli N; Tieghi A; Palumbo GA; Breccia M; Sabattini E; Villari L; Riminucci M; Valli R; Catani L; Alimena G; Ottaviani E; Fama A; Martinelli G; Perricone M; Spinsanti M; Cavo M; Vianelli N; Palandri F
    Hematol Oncol; 2018 Feb; 36(1):269-275. PubMed ID: 28509339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The JAK2V617F allele burden and STAT3- and STAT5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis.
    Risum M; Madelung A; Bondo H; Bzorek M; Kristensen MH; Stamp IM; Hasselbalch HC
    APMIS; 2011 Aug; 119(8):498-504. PubMed ID: 21749449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden.
    Bertozzi I; Bogoni G; Biagetti G; Duner E; Lombardi AM; Fabris F; Randi ML
    Ann Hematol; 2017 Aug; 96(8):1297-1302. PubMed ID: 28585070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia.
    Antonioli E; Guglielmelli P; Poli G; Bogani C; Pancrazzi A; Longo G; Ponziani V; Tozzi L; Pieri L; Santini V; Bosi A; Vannucchi AM;
    Haematologica; 2008 Jan; 93(1):41-8. PubMed ID: 18166784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time.
    Lasho TL; Pardanani A; McClure RF; Mesa RA; Levine RL; Gilliland DG; Tefferi A
    Br J Haematol; 2006 Dec; 135(5):683-7. PubMed ID: 17107350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia.
    Mesa RA; Powell H; Lasho T; Dewald G; McClure R; Tefferi A
    Leuk Res; 2006 Nov; 30(11):1457-60. PubMed ID: 16563504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The decrease of JAK2 V617F allele burden in leukemia transformation of an elderly patient with myelofibrosis.
    Zhang SJ; Li JY; Zhang JF; Finn J; Lu H; Xu W; Qian SX; Wu HX
    Leuk Res; 2009 Aug; 33(8):e116-8. PubMed ID: 19328546
    [No Abstract]   [Full Text] [Related]  

  • 20. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance.
    Wolanskyj AP; Lasho TL; Schwager SM; McClure RF; Wadleigh M; Lee SJ; Gilliland DG; Tefferi A
    Br J Haematol; 2005 Oct; 131(2):208-13. PubMed ID: 16197451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.